All time highs for CGS this morning. The U.S. Food and Drug Administration (FDA)has granted Accelerated Approval for aducanumab (to be marketed as ADUHELMTM) for the treatment of Alzheimer’s disease.
Clinical trials have indicated that ADUHELM may result in a reduction in clinical decline for Alzheimer patients. Biogen will conduct a controlled trial to verify the clinical benefit of ADUHELM in patients with Alzheimer’s disease. If the trial fails to verify clinical benefit, the FDA may initiate proceedings to withdraw approval of the drug.
Bit of a gamble here, but if ADUHELM turns out to be an effective treatment for Alzheimer’s this stock could be huge. Just another day in the biotech casino.
Be the first to comment